Status:
COMPLETED
Tranexamic Acid Dosage for Topical Treatment of Anterior Epistaxis
Lead Sponsor:
Izmir Ataturk Training and Research Hospital
Conditions:
Anterior Epistaxis
Tranexamic Acid
Eligibility:
All Genders
18-92 years
Phase:
PHASE4
Brief Summary
Patients with epistaxis usually apply to the emergency department for initial treatment. According to recent research, tranexamic acid is effective in the treatment of epistaxis. The research compare ...
Detailed Description
This randomized, double-blinded, phase-4 study was conducted in a single center between July and December 2022. Among the patients aged 18 years and older who applied to the emergency department with...
Eligibility Criteria
Inclusion
- 18 years and older
- Those who applied to the emergency department with the complaint of nosebleeds
- Those who agreed to participate in the study by giving written consent
Exclusion
- posterior epistaxis
- history of nose or pharynx surgery in the last 3 months,
- facial and head trauma,
- unstable vital signs,
- who applied for the second time with a recurrent bleeding
- history of allergy to TXA,
- subarachnoid hemorrhage,
- coagulation disorders such as hemophilia, hereditary telangiectasia, von Willebrand disease, etc.
- thromboembolic disease
- history of convulsions
- intracerebral processes
- pregnant or lactating
- who wished to withdraw from the study at any stage of the study
Key Trial Info
Start Date :
December 16 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 15 2023
Estimated Enrollment :
152 Patients enrolled
Trial Details
Trial ID
NCT06183918
Start Date
December 16 2021
End Date
March 15 2023
Last Update
December 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ataturk 'Training and Research Hospital
Izmir, Basın Sitesi, Turkey (Türkiye), 35360